CR20160098A - Polimorfo de los inhibidores de la syk - Google Patents

Polimorfo de los inhibidores de la syk

Info

Publication number
CR20160098A
CR20160098A CR20160098A CR20160098A CR20160098A CR 20160098 A CR20160098 A CR 20160098A CR 20160098 A CR20160098 A CR 20160098A CR 20160098 A CR20160098 A CR 20160098A CR 20160098 A CR20160098 A CR 20160098A
Authority
CR
Costa Rica
Prior art keywords
polymorph
syk inhibitors
bimesylate
polymorphs
salt
Prior art date
Application number
CR20160098A
Other languages
English (en)
Inventor
Peter Chee-Chu Fung
Dimitrios Stefanidis
Dragos Vizitiu
Tim G Elford
Michael Laird Hurrey
Original Assignee
Gilead Connecticut Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51301367&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20160098(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Connecticut Inc filed Critical Gilead Connecticut Inc
Publication of CR20160098A publication Critical patent/CR20160098A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan los polimorfos de la sal bimesilato de un compuesto de la Fórmula I, o un hidrato de la misma. También sepuede representar la sal bimesilato como un compuesto de laFórmula IA. En este documento también se proporcionan lascomposiciones de los mismos, los métodos para su preparacióny los métodos para la obtención de dichos polimorfos.
CR20160098A 2013-07-30 2016-02-29 Polimorfo de los inhibidores de la syk CR20160098A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361860197P 2013-07-30 2013-07-30
PCT/US2014/048733 WO2015017460A1 (en) 2013-07-30 2014-07-29 Polymorph of syk inhibitors

Publications (1)

Publication Number Publication Date
CR20160098A true CR20160098A (es) 2016-07-11

Family

ID=51301367

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160098A CR20160098A (es) 2013-07-30 2016-02-29 Polimorfo de los inhibidores de la syk

Country Status (33)

Country Link
US (4) US20160168155A1 (es)
EP (1) EP3027618B1 (es)
JP (1) JP6230709B2 (es)
KR (1) KR101810798B1 (es)
CN (1) CN105452252A (es)
AP (1) AP2016009008A0 (es)
AR (1) AR097158A1 (es)
AU (2) AU2014296308C1 (es)
CA (1) CA2919661C (es)
CL (1) CL2016000238A1 (es)
CR (1) CR20160098A (es)
DK (1) DK3027618T3 (es)
EA (2) EA201791873A1 (es)
ES (1) ES2822285T3 (es)
HK (1) HK1222390A1 (es)
HR (1) HRP20201582T1 (es)
HU (1) HUE052090T2 (es)
IL (1) IL243579A0 (es)
MD (1) MD4659B1 (es)
MX (1) MX2016001304A (es)
MY (1) MY176803A (es)
NZ (1) NZ715776A (es)
PE (1) PE20160862A1 (es)
PH (1) PH12016500169A1 (es)
PL (1) PL3027618T3 (es)
PT (1) PT3027618T (es)
PY (1) PY1432622A (es)
SG (1) SG11201600385TA (es)
SI (1) SI3027618T1 (es)
SV (1) SV2016005149A (es)
TW (1) TW201602108A (es)
UY (1) UY35683A (es)
WO (1) WO2015017460A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011006094A (es) 2008-12-08 2011-11-29 Gilead Connecticut Inc Inhibidores de imidazopirazina syk.
AU2011226689B2 (en) 2010-03-11 2016-09-01 Kronos Bio, Inc. Imidazopyridines Syk inhibitors
AU2014296308C1 (en) * 2013-07-30 2018-09-13 Kronos Bio, Inc. Polymorph of Syk inhibitors
US9918939B2 (en) * 2013-07-30 2018-03-20 Gilead Connecticut, Inc. Formulation of Syk inhibitors
EA201690608A1 (ru) 2013-12-04 2016-12-30 Джилид Сайэнс, Инк. Способы лечения раковых заболеваний
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
KR20170029580A (ko) 2014-07-14 2017-03-15 길리애드 사이언시즈, 인코포레이티드 암을 치료하기 위한 조합물
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
CN107530354A (zh) 2015-04-21 2018-01-02 吉利德科学公司 使用syk抑制剂对慢性移植物抗宿主病的治疗
WO2017106564A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
US10472369B2 (en) * 2016-02-26 2019-11-12 Crystal Pharmatech Co., Ltd. Crystalline forms of (6-(1H-indazol-6-yl)-N-[4-(4-(4-morpholinyl)phenyl]imidazo[1,2-A]pyrazin-8-amine) methanesulfonate
CA3036384A1 (en) 2016-09-14 2018-03-22 Gilead Sciences, Inc. Syk inhibitors
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
WO2018195471A1 (en) 2017-04-21 2018-10-25 Gilead Sciences, Inc. Syk inhibitors in combination with hypomethylating agents
CA3073871A1 (en) 2017-08-25 2019-02-28 Gilead Sciences, Inc. Polymorphs of syk inhibitors
AU2019222644B2 (en) 2018-02-13 2021-04-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
EP3793565B1 (en) 2018-05-14 2022-01-05 Gilead Sciences, Inc. Mcl-1 inhibitors
JP7407740B2 (ja) 2018-05-18 2024-01-04 ノバルティス アーゲー Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態
SI3820572T1 (sl) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CA3130848A1 (en) 2019-02-22 2020-08-27 Kronos Bio, Inc. Solid forms of condensed pyrazines as syk inhibitors
CN113402506B (zh) * 2021-06-17 2023-06-16 四川大学 中间体和制备方法及其在合成长春布宁上的应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607813B1 (fr) 1986-12-05 1989-03-31 Montpellier I Universite Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique
US5137876A (en) 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
DE4327027A1 (de) 1993-02-15 1994-08-18 Bayer Ag Imidazoazine
DE4337611A1 (de) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE4337609A1 (de) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
FR2711993B1 (fr) 1993-11-05 1995-12-01 Rhone Poulenc Rorer Sa Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation.
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
EP0751926B1 (en) 1994-03-25 2007-09-12 Isotechnika,Inc. Enhancement of the efficacy of drugs by deuteration
FR2723373B1 (fr) 1994-08-02 1996-09-13 Rhone Poulenc Rorer Sa Forme purifiee de streptogramines, sa preparation et les compositions pharmaceutiques qui la contiennent
AU5348396A (en) 1995-05-01 1996-11-21 Fujisawa Pharmaceutical Co., Ltd. Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivati ves and their use as bone resorption inhibitors
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
SE9704404D0 (sv) 1997-11-28 1997-11-28 Astra Ab New compounds
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
JP2004528295A (ja) 2001-01-30 2004-09-16 サイトピア ピーティワイ リミテッド キナーゼ阻害方法
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
BR0307735A (pt) 2002-02-19 2005-01-25 Upjohn Co Carboxamidas heteroaromáticas com ligação-n em ponte biciclìcas fundidas para o tratamento de doença
CA2482991A1 (en) 2002-04-19 2003-10-30 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines method of making and method of use thereof
WO2003095447A1 (en) 2002-05-14 2003-11-20 Xenova Limited Process for the preparation of a hydrate of an anthranilic acid derivative
AU2003270489A1 (en) 2002-09-09 2004-03-29 Cellular Genomics, Inc. 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
KR20050052500A (ko) 2002-09-19 2005-06-02 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 이미다조피리딘
EP1542693A1 (en) 2002-09-23 2005-06-22 Shering Corporation Novel imidazopyrazines as cyclin dependent kinase inhibitors
US6919341B2 (en) 2002-09-23 2005-07-19 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
US7160885B2 (en) 2003-02-10 2007-01-09 Cgi Pharmaceuticals, Inc. Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US20060183746A1 (en) 2003-06-04 2006-08-17 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
US7259164B2 (en) 2003-08-11 2007-08-21 Cgi Pharmaceuticals, Inc. Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
US20050288295A1 (en) 2003-11-11 2005-12-29 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005085252A1 (en) 2004-03-04 2005-09-15 Biofocus Discovery Limited Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
MX2007005643A (es) 2004-11-10 2008-03-13 Cgi Pharmaceuticals Inc Ciertas imidazo [1,2-a] pirazin-8-ilaminas, metodo para su elaboracion y metodo de uso de las mismas.
WO2007040650A2 (en) 2005-05-12 2007-04-12 Abbott Laboratories Apoptosis promoters
BRPI0618520A2 (pt) 2005-11-10 2011-09-06 Schering Corp imidazopirazinas como inibidores de proteìna cinase
CA2662074A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
PE20080839A1 (es) 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
ES2653887T3 (es) 2007-11-28 2018-02-09 Irx Therapeutics, Inc. Procedimiento para aumentar el efecto inmunológico
WO2009077334A1 (en) 2007-12-14 2009-06-25 F. Hoffmann-La Roche Ag Novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives
EP2252617A1 (en) 2008-02-13 2010-11-24 CGI Pharmaceuticals, Inc. 6-aryl-imidaz0[l, 2-a]pyrazine derivatives, method of making, and method of use thereof
CN102014910A (zh) 2008-03-07 2011-04-13 美国辉瑞有限公司 在无食物条件下施用齐拉西酮的方法、剂型和试剂盒
PE20100851A1 (es) 2008-06-24 2011-01-31 Hoffmann La Roche PIRIDIN-2-ONAS Y PIRIDAZIN-3-ONAS SUSTITUIDAS COMO INHIBIDORES DE Btk
WO2010000633A1 (en) 2008-07-02 2010-01-07 F. Hoffmann-La Roche Ag Novel phenylpyrazinones as kinase inhibitors
CA2726460C (en) 2008-07-15 2017-02-21 F. Hoffmann-La Roche Ag Novel phenyl-imidazopyridines and pyridazines
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
MX2011006091A (es) 2008-12-08 2011-11-29 Gilead Connecticut Inc Inhibidores de imidazopirazina syk.
MX2011006094A (es) 2008-12-08 2011-11-29 Gilead Connecticut Inc Inhibidores de imidazopirazina syk.
US8450321B2 (en) * 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
DK2512455T3 (en) 2009-12-18 2014-03-24 Frieslandcampina Nederland Holding B V Co-treated tablet adjuvant composition, its preparation and use
AU2011226689B2 (en) 2010-03-11 2016-09-01 Kronos Bio, Inc. Imidazopyridines Syk inhibitors
RU2628560C2 (ru) 2010-11-23 2017-08-18 Эббви Инк. Соли и кристаллические формы индуцирующего апоптоз агента
TW201247659A (en) * 2011-04-27 2012-12-01 Daiichi Sankyo Co Ltd Crystals of phenylpyrrole derivatives
WO2013188856A1 (en) 2012-06-14 2013-12-19 Gilead Connecticut, Inc. Imidazopyrazine syk inhibitors
HK1210049A1 (en) 2012-08-14 2016-04-15 Gilead Calistoga Llc Combination therapies for treating cancer
US20140148430A1 (en) 2012-11-26 2014-05-29 Gilead Connecticut, Inc. Imidazopyridines syk inhibitors
US9918939B2 (en) * 2013-07-30 2018-03-20 Gilead Connecticut, Inc. Formulation of Syk inhibitors
AU2014296308C1 (en) 2013-07-30 2018-09-13 Kronos Bio, Inc. Polymorph of Syk inhibitors
PT3027601T (pt) 2013-07-31 2018-01-08 Gilead Sciences Inc Inibidores de syk
EA201690608A1 (ru) * 2013-12-04 2016-12-30 Джилид Сайэнс, Инк. Способы лечения раковых заболеваний
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
ES2724460T3 (es) 2013-12-23 2019-09-11 Gilead Pharmasset Llc Síntesis de un tripéptido que inhíbe el NS3 del virus de VHC macrocíclico
TW201617074A (zh) 2014-07-14 2016-05-16 吉李德科學股份有限公司 Ｓｙｋ（脾酪胺酸激酶）抑制劑
KR20170029580A (ko) 2014-07-14 2017-03-15 길리애드 사이언시즈, 인코포레이티드 암을 치료하기 위한 조합물
TW201639573A (zh) * 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
CN107530354A (zh) 2015-04-21 2018-01-02 吉利德科学公司 使用syk抑制剂对慢性移植物抗宿主病的治疗

Also Published As

Publication number Publication date
AP2016009008A0 (en) 2016-01-31
KR101810798B1 (ko) 2017-12-19
US10266539B2 (en) 2019-04-23
SG11201600385TA (en) 2016-02-26
EP3027618A1 (en) 2016-06-08
CL2016000238A1 (es) 2016-07-22
SI3027618T1 (sl) 2021-01-29
PH12016500169A1 (en) 2016-04-25
HK1222390A1 (zh) 2017-06-30
US20170217967A1 (en) 2017-08-03
AU2017225136A1 (en) 2017-10-05
TW201602108A (zh) 2016-01-16
MY176803A (en) 2020-08-21
EA201690172A1 (ru) 2016-07-29
AU2014296308B2 (en) 2017-06-08
EA029281B1 (ru) 2018-03-30
AU2014296308C1 (en) 2018-09-13
AU2014296308A1 (en) 2016-02-04
KR20160038007A (ko) 2016-04-06
EP3027618B1 (en) 2020-07-08
PE20160862A1 (es) 2016-09-24
ES2822285T3 (es) 2021-04-30
HRP20201582T1 (hr) 2021-02-19
JP2016527268A (ja) 2016-09-08
WO2015017460A1 (en) 2015-02-05
DK3027618T3 (da) 2020-10-12
AR097158A1 (es) 2016-02-24
US20160168155A1 (en) 2016-06-16
US9657023B2 (en) 2017-05-23
IL243579A0 (en) 2016-02-29
SV2016005149A (es) 2017-04-03
JP6230709B2 (ja) 2017-11-15
HUE052090T2 (hu) 2021-04-28
CN105452252A (zh) 2016-03-30
CA2919661C (en) 2020-08-18
MD20160017A2 (ro) 2016-08-31
PY1432622A (es) 2017-09-01
US20180099971A1 (en) 2018-04-12
PL3027618T3 (pl) 2021-04-19
EA201791873A1 (ru) 2018-09-28
MX2016001304A (es) 2016-04-07
CA2919661A1 (en) 2015-02-05
UY35683A (es) 2015-02-27
US20150038505A1 (en) 2015-02-05
PT3027618T (pt) 2020-10-12
NZ715776A (en) 2017-04-28
MD4659B1 (ro) 2019-11-30

Similar Documents

Publication Publication Date Title
CR20160098A (es) Polimorfo de los inhibidores de la syk
CU24517B1 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
EA201992183A3 (ru) Синтез полициклических карбамоилпиридоновых соединений
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
EA201692219A1 (ru) Способы получения противовирусных соединений
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
UY34445A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
SI3066085T1 (sl) Postopek sinteze inhibitorja indolamina 2,3-dioksigenaze
CR20150061A (es) Compuesto de pirazolopirimidinas
CL2017001131A1 (es) Síntesis de copanlisib y su sal diclorhidrato
CL2017001130A1 (es) Síntesis de copanlisib y su sal diclorhidrato
CY1118079T1 (el) Μεθοδος παρασκευης του αλατος l-αργινινικης περινδοπριλης
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
CR20150006A (es) Metodo para preparar triazolopiridinas sustituidas
EA201690593A1 (ru) Новые соединения мочевины
CY1116366T1 (el) Νεα μεθοδος για τη συνθεση αγομελατινης
PL405775A1 (pl) Nowy związek, zwłaszcza do stosowania jako pigment